The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called ...

ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

In a jobs market marred by a hiring slowdown, Staffline (STAF) appears to be bucking the trend. Unlike its larger peers, the Aim-listed blue-collar recruiter grew revenue, underlying operating profits ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK (LSE: GSK) to develop novel medicines for neurodegenerative diseases by ...

Funds have also been suspended for AIDS Clinical Trial Group, a nearly 40-year-old system that has been responsible for key breakthroughs dating back to the first effective AIDS drug, AZT. All three ...